These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
516 related items for PubMed ID: 21392396
1. Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen. Wu X, Subramaniam M, Grygo SB, Sun Z, Negron V, Lingle WL, Goetz MP, Ingle JN, Spelsberg TC, Hawse JR. Breast Cancer Res; 2011 Mar 10; 13(2):R27. PubMed ID: 21392396 [Abstract] [Full Text] [Related]
2. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells. Secreto FJ, Monroe DG, Dutta S, Ingle JN, Spelsberg TC. J Cell Biochem; 2007 Aug 01; 101(5):1125-47. PubMed ID: 17520659 [Abstract] [Full Text] [Related]
3. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Wu X, Hawse JR, Subramaniam M, Goetz MP, Ingle JN, Spelsberg TC. Cancer Res; 2009 Mar 01; 69(5):1722-7. PubMed ID: 19244106 [Abstract] [Full Text] [Related]
4. Pharmacological relevance of endoxifen in a laboratory simulation of breast cancer in postmenopausal patients. Maximov PY, McDaniel RE, Fernandes DJ, Bhatta P, Korostyshevskiy VR, Curpan RF, Jordan VC. J Natl Cancer Inst; 2014 Oct 01; 106(10):. PubMed ID: 25258390 [Abstract] [Full Text] [Related]
8. Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Buteau-Lozano H, Ancelin M, Lardeux B, Milanini J, Perrot-Applanat M. Cancer Res; 2002 Sep 01; 62(17):4977-84. PubMed ID: 12208749 [Abstract] [Full Text] [Related]
9. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ. Mishra AK, Abrahamsson A, Dabrosin C. Oncotarget; 2016 Aug 30; 7(35):56876-56888. PubMed ID: 27486755 [Abstract] [Full Text] [Related]
10. Estrogen receptor alpha and beta heterodimers exert unique effects on estrogen- and tamoxifen-dependent gene expression in human U2OS osteosarcoma cells. Monroe DG, Secreto FJ, Subramaniam M, Getz BJ, Khosla S, Spelsberg TC. Mol Endocrinol; 2005 Jun 30; 19(6):1555-68. PubMed ID: 15802376 [Abstract] [Full Text] [Related]
11. Potential of endogenous estrogen receptor beta to influence the selective ER modulator ERbeta complex. Chen B, Gajdos C, Dardes R, Kidwai N, Johnston SR, Dowsett M, Jordan VC. Int J Oncol; 2005 Aug 30; 27(2):327-35. PubMed ID: 16010412 [Abstract] [Full Text] [Related]
12. ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancer. Reese JM, Suman VJ, Subramaniam M, Wu X, Negron V, Gingery A, Pitel KS, Shah SS, Cunliffe HE, McCullough AE, Pockaj BA, Couch FJ, Olson JE, Reynolds C, Lingle WL, Spelsberg TC, Goetz MP, Ingle JN, Hawse JR. BMC Cancer; 2014 Oct 07; 14():749. PubMed ID: 25288324 [Abstract] [Full Text] [Related]
15. Generation of stable reporter breast cancer cell lines for the identification of ER subtype selective ligands. Shanle EK, Hawse JR, Xu W. Biochem Pharmacol; 2011 Dec 15; 82(12):1940-9. PubMed ID: 21924251 [Abstract] [Full Text] [Related]
19. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors alpha and beta. Tee MK, Rogatsky I, Tzagarakis-Foster C, Cvoro A, An J, Christy RJ, Yamamoto KR, Leitman DC. Mol Biol Cell; 2004 Mar 15; 15(3):1262-72. PubMed ID: 14699072 [Abstract] [Full Text] [Related]
20. A genome-wide study of the repressive effects of estrogen receptor beta on estrogen receptor alpha signaling in breast cancer cells. Williams C, Edvardsson K, Lewandowski SA, Ström A, Gustafsson JA. Oncogene; 2008 Feb 07; 27(7):1019-32. PubMed ID: 17700529 [Abstract] [Full Text] [Related] Page: [Next] [New Search]